Shares of MiMedx Group, Inc. (NASDAQ:MDXG – Get Free Report) have been given an average rating of “Buy” by the five brokerages that are currently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $12.00.
MDXG has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 target price on shares of MiMedx Group in a research report on Thursday, August 1st. Craig Hallum cut their price target on MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Finally, StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 4th.
Check Out Our Latest Research Report on MDXG
Hedge Funds Weigh In On MiMedx Group
MiMedx Group Stock Down 1.6 %
Shares of NASDAQ MDXG opened at $6.13 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.22 and a current ratio of 3.85. MiMedx Group has a 52 week low of $5.57 and a 52 week high of $9.27. The stock has a market capitalization of $904.81 million, a P/E ratio of 13.93 and a beta of 1.98. The stock’s fifty day moving average is $6.67 and its 200 day moving average is $7.01.
MiMedx Group (NASDAQ:MDXG – Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. The firm had revenue of $87.21 million for the quarter, compared to analysts’ expectations of $88.44 million. Sell-side analysts forecast that MiMedx Group will post 0.26 earnings per share for the current fiscal year.
About MiMedx Group
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Recommended Stories
- Five stocks we like better than MiMedx Group
- Investing In Automotive Stocks
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- How Investors Can Find the Best Cheap Dividend Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Why Are These Companies Considered Blue Chips?
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.